Premium
Unnatural milieu: Thrombus after transcatheter mitral valve replacement
Author(s) -
Khan Jaffar M.,
Lederman Robert J.
Publication year - 2017
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27229
Subject(s) - medicine , vitamin k antagonist , thrombus , thrombosis , cardiology , mitral valve , valve replacement , prospective cohort study , heart valve , mitral valve replacement , surgery , atrial fibrillation , warfarin , stenosis
Key PointsWhat the article teaches Transcatheter heart valve thrombosis in the mitral position causes increased valve gradients, valve dysfunction, and symptoms, and may be associated with lack of therapeutic anticoagulation. How it will impact practice Anticoagulation with a vitamin K antagonist should be considered in all patients undergoing transcatheter mitral valve replacement. What new research/study would help answer the question posed Efficacy, optimal duration, and safety of anticoagulation therapy, balancing reduced thrombosis against increased bleeding risk, needs to be assessed in larger cohort studies and prospective trials.